The pharmacological modulation of Nrf2/ARE by HO-1 and its bioactive compounds serve as a potential therapeutic target to suppress AR levels and sanitize PCa to anti-androgens therapy [57]. The gene discussed is NFE2L2; the disease is posterior cortical atrophy.